12 results about "Pneumovirus" patented technology

The invention discloses a pneumovirus gene data multi-view clustering integration method and device and electronic equipment. The method comprises the following steps: constructing a width self-encoder with a width learning network and a global subspace structure; training a width auto-encoder, determining model parameters of the width auto-encoder, inputting multi-view pneumonia gene data into the trained width auto-encoder, and outputting a compressed feature subspace; clustering the compressed feature subspaces to obtain a plurality of basic partitions as integration members of an integration pool; the basic partition is converted into a fuzzy partition matrix, an undirected bipartite graph is constructed based on the integration pool, and connection weights between nodes of the undirected bipartite graph correspond to values in the fuzzy partition matrix; and cutting the undirected bipartite graph into several disjoint sub-graphs, and obtaining a clustering integration result of multi-view pneumonia gene data according to the sample nodes of each sub-graph. According to the method, parameter quantity and computing resources are remarkably reduced, and multi-view clustering analysis of pneumonia gene data is efficiently completed.

The invention provides a probe library for high-throughput detection of mouse and hamster related species-specific viruses in a CHO cell library and application of the probe library. The probe library is used for detecting a mouse pox virus, a hantavirus, a K virus, a lactic dehydrogenase virus, a lymphocytic choriomeningitis virus, a mouse microvirus, a mouse adenovirus, a mouse cytomegalovirus, a mouse encephalomyelitis virus, a mouse hepatitis virus, a mouse rotavirus, a mouse pneumovirus, a multiple oma virus, a reovirus type 3 and a sendai virus; sV5 and thymoviruses and variant viruses thereof. The high-throughput sequencing method based on the probe library can be used for distinguishing viral nucleic acid with infection risk and quickly checking whether a sample is polluted by specific live viruses or not. The detection limit reaches the level of a traditional PCR method, the capability of detecting all known variants of to-be-detected species-specific viruses is kept, 17 viruses can be detected only by implementing one detection item, and the method has the advantages of high efficiency, rapidness and high sensitivity.

Disclosed herein are nanostructures and uses thereof, comprising a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1, and I53_dn5A.2, or variants thereof, and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides that are I53_dn5B or a variant thereof, wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form the nanostructure; and the nanostructure displays multiple copies of F protein or antigenic fragment thereof of one or more paramyxoviruses and / or pneumoviruses, respectively.

Disclosed herein are nanostructures and their use, where the nanostructures include(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; andwherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 10-10° bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human Orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human Metapneumovirus (hMPV) infections.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

The invention relates to the field of virus genetic manipulation, in particular to a mouse pneumovirus reverse genetic manipulation system and application thereof. The system comprises: (1) a transcription plasmid, wherein the transcription plasmid can transcribe a genome full-length cDNA sequence of the mouse pneumovirus; (2) a plurality of helper plasmids, wherein the helper plasmids can respectively express N protein, P protein, M2-1 protein and L protein of the mouse pneumovirus; (3) a plasmid for expressing T7 polymerase; wherein the transcription plasmid also transcripts a gene for coding a foreign protein at the same time, and the gene for coding the foreign protein is located between the gene for coding the SH protein and the gene for coding the G protein of the mouse pneumovirus. According to the invention, the problems of low efficiency and complex operation of the mouse pneumovirus reverse genetic system are improved, and the system stability is enhanced.

The present invention relates to stable pre-fusion human pneumovirus (HMPV) F proteins, nucleic acid molecules encoding said HMPV F proteins and uses thereof.

Chimeric polypeptides, chimeric fusion proteins, immunogenic compositions, and methods of use thereof for pan-pneumovirus vaccination are provided. The chimeric polypeptides typically include immunodominant epitopes of the fusion protein of respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), and preferably include one or more of antigenic sites Ø, V, and II of RSV, and III, IV, and DS7 of hMPV. The chimeric polypeptides can be utilized as the antigenic domain in chimeric fusion proteins include one or more additional domains such as a signal peptide sequence, a trimerization domain, a cleavage site, a purification tag or report sequence, and one or more linker sequences. Nucleic acids encoding the chimeric polypeptides and chimeric fusion proteins are also provided, as are recombinant viruses having the same. Pharmaceutical compositions including one or more of the foregoing compositions, and methods of there use for immunizing subjects against RSV and hMPV are also provided.

Disclosed herein are nanostructures and their use, where the nanostructures include (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide; wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; and wherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

Disclosed herein are nanostructures and their use, where the nanostructures include(a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides;(b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, wherein the second polypeptide differs from the first polypeptide;wherein the plurality of first assemblies non-covalently interact with the plurality of second assemblies to form a nanostructure; andwherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, on an exterior of the nanostructure.

To provide subunit vaccines with nanostructure-based vaccines.SOLUTION: Provided herein are nanostructures and their use, where the nanostructures include: a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides selected from I53_dn5A, I53_dn5A.1 and I53_dn5A.2, or variants thereof; and a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides being I53_dn5B or a variant thereof; where the first assemblies non-covalently interact with the second assemblies to form a nanostructure; and where the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof.SELECTED DRAWING: None